Crossmark

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

Crossref DOI link: https://doi.org/10.1186/s41120-018-0021-5

Published Online: 2018-02-07

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jani, Darshana https://orcid.org/0000-0002-6329-7759
Nowak, John

Chen, Ying

Boni, Joseph

Gorovits, Boris
License Information

Text and Data Mining valid from 2018-02-07
More Information

Article History

Received: 10 October 2017

Accepted: 15 January 2018

First Online: 7 February 2018

Competing interests

: DJ, JN, YC, JB, and BG were stockholders and employees of Pfizer Inc at the time of study.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.